<!doctype html>
<html lang="zh-Hant">

<head>
    <?php include "header-title.php"; ?>

</head>

<body>
    <div class="wp">
        <?php include "header.php"; ?>
        <!-- main ======================================================================================= -->
        <main class="main">
            <div class="editor" id="promotionEditor">
                <div class="banner flex-center text-white background-cover" style="background-image:url(styles/images/promotions/banner.jpg)">
                    <div class="text-center">
                        <h1 class="font-56 font-weight-bold" data-aos="fade-up">潛力案源</h1>
                        <p class="font-26 font-weight-bold" data-aos="fade-up" data-aos-delay="50">研發成果創業加速及整合推廣</p>
                    </div>
                </div>
                <div class="blank font-22 py-5 px-4">
                    <div class="max1520 border-bottom-FEA610  mt-1">
                        <div class="max1320 mx-auto pb-2">
                            <div class="d-table pl-md-4">
                                <a class="flex-align-center text-308D9B" href="" data-aos="fade-up">
                                    <i class="icon-left-open-big font-16 mr-3"></i>
                                    <span class="">返回列表</span>
                                </a>
                            </div>
                            <div class="mt-4 pt-lg-3">
                                <div class="d-block d-md-flex flex-justify-space-between pl-md-4 mb-3 mb-md-0">
                                    <div class="pr-md-5 mr-xl-5 mb-2 mb-md-0">
                                        <span class="d-block text-808080" data-aos="fade-up">D17A0002</span>
                                        <h2 class="font-30 font-weight-bold mb-0" data-aos="fade-up">作用於血小板血栓素受體的抗血栓小分子先導藥物之研發</h2>
                                        <p class="font-weight-bold" data-aos="fade-up">Development of anti-thrombotic small molecule lead drugs acting on platelet thromboxane receptors</p>
                                    </div>
                                    <div>
                                        <img src="styles/images/promotion/nbp.jpg" alt="">
                                    </div>
                                </div>
                                <div class="bg-CCCCCC02 py-4 px-3 px-md-4 mt-2 mb-4 mb-lg-5" data-aos="fade-up">
                                    <div class="py-md-3">
                                        <p class="mb-2">本產品螢光醣類衍生物(螢光醣)為醣分子與胺基分子組合而成的水溶性、結構穩定之小分子，物性上具極高螢光強度、不易光漂白，只需簡易LED激。本產品螢光醣類衍生物(螢光醣)為醣分子與胺基分子組合而成的水溶性、結構穩定之小分子，物性上具極高螢光強度。</p>
                                        <p class="mb-0">The fluorescent sugar derivatives (fluorescent sugars) of this product are water-soluble and structurally stable small molecules composed of sugar molecules and amine-based molecules. The physical properties have extremely high fluorescent intensity and are not easy to photobleach. Only simple LED excitation is required.</p>
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                    <div class="max1520 border-bottom-FEA610 pb-lg-5 mb-4">
                        <div class="max1320 mx-auto pt-4 mt-2">
                            <span class="d-block font-24 font-weight-bold pl-4" data-aos="fade-up">未定中標題</span>
                            <div class="row g-0 pt-4 mt-1">
                                <div class="col-12 col-md-5">
                                    <div class="pb-3 pb-md-4 mb-md-2" data-aos="fade-up">
                                        <span class="flex-align-center border-bottom-D7D7D7 pb-2 mb-2">
                                            <img class="mb-1" src="styles/images/promotion/list.png" alt="">
                                            <span class="d-block font-25 text-308D9B font-weight-bold ml-2 ml-md-3 mb-md-1">Targeted indication</span>
                                        </span>
                                        <div class="pt-md-1 pl-3 pl-md-4">
                                            <p>Acute Myocardial Infarction and thrombotic stroke</p>
                                        </div>
                                    </div>
                                    <div class="pb-3 pb-md-4 mb-md-2" data-aos="fade-up">
                                        <span class="flex-align-center border-bottom-D7D7D7 pb-2 mb-2">
                                            <img class="mb-1" src="styles/images/promotion/list.png" alt="">
                                            <span class="d-block font-25 text-308D9B font-weight-bold ml-2 ml-md-3 mb-md-1">Status</span>
                                        </span>
                                        <div class="pt-md-1 pl-3 pl-md-4">
                                            <p>Pre-clinical studies.</p>
                                        </div>
                                    </div>
                                </div>
                                <div class="col-12 col-md-7 pl-md-5">
                                    <div class="pb-3 pb-md-4 mb-md-2 pl-lg-4" data-aos="fade-up">
                                        <span class="flex-align-center border-bottom-D7D7D7 pb-2 mb-2">
                                            <img class="mb-1" src="styles/images/promotion/list.png" alt="">
                                            <span class="d-block font-25 text-308D9B font-weight-bold ml-2 ml-md-3 mb-md-1">Key features</span>
                                        </span>
                                        <div class="pt-md-1 pl-3 pl-md-4">
                                            <ul class="noneStyle gray-ul-dots">
                                                <li>High anti-platelet and anti-thrombotic efficacy </li>
                                                <li>Highly stable IIb3 antagonist with a stable pharmacokinetic profile</li>
                                                <li>Favorable safety profile with no thrombocytopenia and bleeding side effects</li>
                                            </ul>
                                        </div>
                                    </div>
                                </div>
                                <div class="col-12">
                                    <div class="pb-3 pb-md-4 mb-md-2" data-aos="fade-up">
                                        <span class="flex-align-center border-bottom-D7D7D7 pb-2 mb-2">
                                            <img class="mb-1" src="styles/images/promotion/list.png" alt="">
                                            <span class="d-block font-25 text-308D9B font-weight-bold ml-2 ml-md-3 mb-md-1">Market</span>
                                        </span>
                                        <div class="pt-md-1 pl-3 pl-md-4">
                                            <p>Use of antithrombotic therapy, including antiplatelet and anticoagulant agents, is a vital element in reducing the overall morbidity and mortality in patients with cardiovascular disease. Importantly, RR with very high safety profile can potentially help resolve the issue that clinical anti-thrombotics (i.e., abciximab, eptifibatide, and tirofiban) have significant bleeding risk. Furthermore, RR exhibiting stable pharmacokinetic profile given by intramuscular injection offers greater convenience to patients and reduces overall healthcare costs compared to standard IV infusion. </p>
                                        </div>
                                    </div>
                                </div>
                            </div>
                            <div class="row g-5">
                                <div class="col-12 mb-4 pb-md-3">
                                    <p class="font-25 text-white bg-308D9B font-weight-bold py-1 py-md-2 px-3 px-md-4 mb-3 mb-md-4" data-aos="fade-up">
                                        <span class="d-block my-md-1">MODE OF ACTION</span>
                                    </p>
                                    <div class="px-3 px-md-4" data-aos="fade-up">
                                        <p><span class="font-weight-bold">RR</span> is a selective inhibitor of IIb3 that can prevents thrombosis and minimizes hemorrhage.</p>
                                        <img class="my-3" src="styles/images/promotion/1.jpg" alt="">
                                        <p>Current IIb3 antagonists are effective anti-thrombotics but have significant bleeding risk. Disintegrin TMV-7 and its derivative RR prevent thrombosis by selectively inhibiting integrin outside-in signaling without affecting processes of hemostasis (i.e., platelet adhesion and clot retraction) in human thrombin-activated platelets, thus they do not increase bleeding risk and have a greater safety profile than the current IIb3 antagonists (i.e., Eptifibatide).</p>
                                    </div>
                                </div>
                                <div class="col-12 mb-4 pb-md-3" data-aos="fade-up">
                                    <p class="font-25 text-white bg-308D9B font-weight-bold py-1 py-md-2 px-3 px-md-4 mb-3 mb-md-4" data-aos="fade-up">
                                        <span class="d-block my-md-1">EXPERIMENTAL RESULTS</span>
                                    </p>
                                    <div class="px-3 px-md-4" data-aos="fade-up">
                                        <div class="pb-4">
                                            <span class="d-block font-25 font-weight-bold text-308D9B mb-2">In vitro efficacy</span>
                                            <p>TMV-7, and TMV-7 mutant RR inhibit agonist-induced human platelet aggregation through IIb3 receptor blockade, especially RR exhibits higher potency in inhibiting platelet aggregation and its safety index is raised to 260-time higher than eptifibatide in human platelet suspension.</p>
                                        </div>
                                        <div class="pb-4">
                                            <span class="d-block font-25 font-weight-bold text-308D9B mb-2">In viVo efficacy</span>
                                            <p>The anti-platelet and thrombotic efficacy of RR has been proven in mouse and pig models; RR neither prolonged the bleeding time nor reduced in platelet counts in the bleeding tendency in both animal models.</p>
                                            <img class="my-3" src="styles/images/promotion/2.jpg" alt="">
                                        </div>
                                        <div class="pb-4 pb-md-5">
                                            <span class="d-block font-25 font-weight-bold text-308D9B mb-2">Safety pharmacology and general toxicology</span>
                                            <p class="mb-0"> ‧ At doses up to 20 times the clinical dose of RR, no prolonging tail-bleeding time and thrombocytopenia are observed in FcRIIa transgenic mice in vivo.</p>
                                            <p class="mb-4"> ‧ At doses up to 3 times the clinical dose of RR, no defected hemostatic function and toxicological findings are observed in pigs in vivo.</p>
                                            <p class="mb-4">RR does not impair the appropriate balance between potent antithrombotic effects and physiological hemostasis as revealed by in vivo thrombosis model and bleeding time test.</p>
                                        </div>
                                        <div>
                                            <span class="d-block font-25 font-weight-bold text-308D9B mb-2">Pharmaceutical development</span>
                                            <p class="mb-0"> ‧ Drug product as a solution for injection is stable for minimum 40 hours.</p>
                                            <p class="mb-0"> ‧ A new PEGylated RR provides enhancing pharmaceutical advantages and pharmacokinetic characterization.</p>
                                            <p class="mb-0"> ‧ The optimal small-molecules mimetics are being developed with NMR studies and computer modeling.</p>
                                        </div>
                                    </div>
                                </div>
                                <div class="col-12 col-md-6 mb-4 pb-md-3">
                                    <p class="font-25 text-white bg-308D9B font-weight-bold py-1 py-md-2 px-3 px-md-4 mb-3 mb-md-4" data-aos="fade-up">
                                        <span class="d-block my-md-1">INTELLECTUAL PROPERTY</span>
                                    </p>
                                    <div class="px-3 px-md-4" data-aos="fade-up">
                                        <div class="mb-2">
                                            <p class="mb-0">Kuo et al., 2017. J Thromb Haemost.</p>
                                            <p class="mb-0">doi: 10.1111/jth.13803</p>
                                        </div>
                                        <div class="mb-2">
                                            <p class="mb-0">Kuo et al., 2017. ISTH Conference.</p>
                                            <p class="mb-0">dAbstract A-859-0079-00721</p>
                                        </div>
                                        <p class="mb-2">Hung et al., 2017. Eur J Pharmacol. 813:24-32</p>
                                        <p class="mb-2">Huang et al., 2016. Thromb J. 14(Suppl 1):18</p>
                                    </div>
                                </div>
                                <div class="col-12 col-md-6 mb-4 pb-md-3">
                                    <p class="font-25 text-white bg-308D9B font-weight-bold py-1 py-md-2 px-3 px-md-4 mb-3 mb-md-4" data-aos="fade-up">
                                        <span class="d-block my-md-1">SELECTED PUBLICATIONS</span>
                                    </p>
                                    <div class="px-3 px-md-4" data-aos="fade-up">
                                        <p>Applications of Taiwan and PCT patents </p>
                                    </div>
                                </div>
                                <div class="col-12 col-md-6 mb-4 pb-md-3">
                                    <p class="font-25 text-white bg-308D9B font-weight-bold py-1 py-md-2 px-3 px-md-4 mb-3 mb-md-4" data-aos="fade-up">
                                        <span class="d-block my-md-1">BUSINESS OPPORTUNITY</span>
                                    </p>
                                    <div class="px-3 px-md-4" data-aos="fade-up">
                                        <p>License and/or Collaboration and Sponsored Research</p>
                                    </div>
                                </div>
                                <div class="col-12 col-md-6 mb-4 pb-md-3">
                                    <p class="font-25 text-white bg-308D9B font-weight-bold py-1 py-md-2 px-3 px-md-4 mb-3 mb-md-4" data-aos="fade-up">
                                        <span class="d-block my-md-1">CONTACT</span>
                                    </p>
                                    <div class="px-3 px-md-4" data-aos="fade-up">
                                        <p>Please contact Drug Commercialization Center, TAIWAN at dcc@biip-dcc.org</p>
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                    <div class="pt-3 max1520 mx-auto pb-5 mb-lg-5">
                        <div class="prev_back_next position-relative flex-align-center flex-justify-space-between" data-aos="fade-up">
                            <div>
                                <a class="flex-align-center text-808080" href="new">
                                    <i class="icon-left-open-big font-16 mr-2 mr-md-4"></i>
                                    <span class="d-block">
                                        <span class="d-none d-md-block font-16">Previous</span>
                                        <span class="font-weight-500 line1">邀請您參加「中美戰疫新創籌資的困境...</span>
                                    </span>
                                </a>
                            </div>
                            <a href="news" class="back absolute-center text-center text-808080 text-hover-FEA610">
                                <i class="icon-block font-22 text-FEA610"></i>
                                <span class="d-block font-16 mt-2 pt-md-1">回列表</span>
                            </a>
                            <div class="text-right">
                                <a class="flex-align-center text-808080" href="new">

                                    <span class="d-block">
                                        <span class="d-none d-md-block font-16">Next</span>
                                        <span class="font-weight-500 line1">「2018創新醫電與醫學影像國際商機論壇...</span>
                                    </span>
                                    <i class="icon-right-open-big font-16 ml-2 ml-md-4"></i>
                                </a>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
        </main>
        <!-- main ======================================================================================= -->
        <?php include "footer.php"; ?>
    </div>
    <?php include "footer-js.php"; ?>
</body>

</html>